Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date
Serbia: These 16 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027
The content of this page is licensed under a Creative Commons Attribution 4.0 International License.
Generic Entry Dates in Other Countries
Friedman, Yali, "Serbia: These 16 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Serbia?
Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Serbia Patent 52,408
Patent Title: FUMARATNA SO (ALFA S, BETA R)-6-BROMO-ALFA-[2-(DIMETILAMINO)ETIL]-2-METOKSI-ALFA-1-NAFTALENIL-BETA-FENIL-3-KINOLINETANOLA (FUMARATE SALT OF (ALPHA S, BETA R)-6-BROMO-ALPHA-[2-(DIMETHYLAMINO)ETHYL]-2¬METHOXY-ALPHA-1-NAPHTHALENYL-BETA-PHENYL-3-QUlNOLINEETHANOL)
SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.
See drug price trends for SIRTURO.
The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.
When can AMYVID (florbetapir f-18) generic drug versions launch in Serbia?
Generic name: florbetapir f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 26, 2027
Generic Entry Controlled by: Serbia Patent 56,171
AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug. There has been litigation on patents covering AMYVID
The generic ingredient in AMYVID is florbetapir f-18. Additional details are available on the florbetapir f-18 profile page.
When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in Serbia?
Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Serbia Patent 56,036
Patent Title: SOLI PIPERAZINA KAO D3/D2 ANTAGONISTI (PIPERAZINE SALTS AS D3/D2 ANTAGONISTS)

See drug price trends for VRAYLAR.
The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.
When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Serbia?
Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Serbia Patent 55,591
TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.
See drug price trends for TRELSTAR.
The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.
When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Serbia?
Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Serbia Patent 58,248
TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.
See drug price trends for TRELSTAR.
The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.
When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Serbia?
Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Serbia Patent 55,591
TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.
The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.
When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Serbia?
Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Serbia Patent 58,248
TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.
The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.
When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Serbia?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Serbia Patent 53,245
Patent Title: SOLI INHIBITORA JANUS KINAZE (R)-3-(4-(7H-PIROLO(2,3-D) PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-3-CIKLOPENTILPROPAN-NITRILA (SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE)
JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI
See drug price trends for JAKAFI.
The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.
When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Serbia?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Serbia Patent 54,878
Patent Title: KRISTALNE SOLI INHIBITORA JANUS KINAZE (R)-3-(4-(7H-PIROLO[2,3-D]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-3-CIKLOPENTILPROPIONITRIL (CRYSTALLINE SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE)
JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI
See drug price trends for JAKAFI.
The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.
When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Serbia?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Serbia Patent 58,449
Patent Title: UPOTREBA SOLI INHIBITORA JANUS KINAZE (R)-3-(4-(7H-PIROLO[2,3-D]PIRIMIDIN-4-IL)-1H- PIRAZOL-1-IL)-3-CIKLOPENTILPROPIONITRILA (USE OF SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H- PYRAZOL-1-YL)-3- CYCLOPENTYLPROPANENITRILE)
JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI
See drug price trends for JAKAFI.
The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.
When can BYDUREON (exenatide synthetic) generic drug versions launch in Serbia?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Serbia Patent 53,638
Patent Title: KRISTALNI SOLVATI DERIVATA (1S)-1,5-ANHIDRO-1-C-(3-((FENIL) METIL) FENIL)-D-GLUCITOLA SA ALKOHOLIMA KAO INHIBITORI SGLT2 ZA TRETMAN DIJABETESA (CRYSTALLINE SOLVATES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL) METHYL) PHENYL)-D-GLUCITOL DERIVATIVES WITH ALCOHOLS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES)

See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. Additional details are available on the exenatide synthetic profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch in Serbia?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Serbia Patent 53,638
Patent Title: KRISTALNI SOLVATI DERIVATA (1S)-1,5-ANHIDRO-1-C-(3-((FENIL) METIL) FENIL)-D-GLUCITOLA SA ALKOHOLIMA KAO INHIBITORI SGLT2 ZA TRETMAN DIJABETESA (CRYSTALLINE SOLVATES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL) METHYL) PHENYL)-D-GLUCITOL DERIVATIVES WITH ALCOHOLS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES)

See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. Additional details are available on the dapagliflozin profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch in Serbia?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Serbia Patent 53,638
Patent Title: KRISTALNI SOLVATI DERIVATA (1S)-1,5-ANHIDRO-1-C-(3-((FENIL) METIL) FENIL)-D-GLUCITOLA SA ALKOHOLIMA KAO INHIBITORI SGLT2 ZA TRETMAN DIJABETESA (CRYSTALLINE SOLVATES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL) METHYL) PHENYL)-D-GLUCITOL DERIVATIVES WITH ALCOHOLS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES)

See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can WINLEVI (clascoterone) generic drug versions launch in Serbia?
Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Serbia Patent 54,354
Patent Title: KORTEKSOLON-17ALFA-PROPIONAT U KRISTALNOM OBLIKU I (CORTEXOLONE-17ALPHA-PROPIONATE IN CRYSTALLINE FORM I)

See drug price trends for WINLEVI.
The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.
When can WINLEVI (clascoterone) generic drug versions launch in Serbia?
Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Serbia Patent 54,361
Patent Title: KORTEKSOLON-17ALFA-PROPIONAT U KRISTALNOM HIDRATNOM OBLIKU IV (CORTEXOLONE-17ALPHA-PROPIONATE IN HYDRATE CRYSTALLINE FORM IV)

See drug price trends for WINLEVI.
The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.
When can WINLEVI (clascoterone) generic drug versions launch in Serbia?
Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Serbia Patent 58,950
Patent Title: FARMACEUTSKE KOMPOZICIJE KOJE SADRŽE KORTEKSOLON-17-ALFA-PROPIONAT (PHARMACEUTICAL COMPOSITIONS CONTAINING CORTEXOLONE-17-ALPHA-PROPIONATE)

See drug price trends for WINLEVI.
The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.
When can BRILINTA (ticagrelor) generic drug versions launch in Serbia?
Generic name: ticagrelor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 20, 2027
Generic Entry Controlled by: Serbia Patent 55,884
Patent Title: SASTAVI, POGODNI ZA ORALNU PRIMENU KOJI SADRŽE TRIAZOL [4, 5-D]PIRIMIDIN DERIVAT (COMPOSITIONS, SUITABLE FOR ORAL ADMINISTRATION, COMPRISING A TRIAZOLO [4, 5-D]PYRIMIDIN DERIVATE)

See drug price trends for BRILINTA.
The generic ingredient in BRILINTA is ticagrelor. Additional details are available on the ticagrelor profile page.
When can ZYKADIA (ceritinib) generic drug versions launch in Serbia?
Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: Serbia Patent 53,588
Patent Title: JEDINJENJA I KOMPOZICIJE KAO INHIBITORI PROTEIN KINAZA (COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS)
ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.
See drug price trends for ZYKADIA.
The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.
When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Serbia?
Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Serbia Patent 53,569
Patent Title: NOVA JEDINJENJA I KOMPOZICIJE, TE POSTUPCI ZA UPOTREBU (NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE)

See drug price trends for DUZALLO.
The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.
When can ZURAMPIC (lesinurad) generic drug versions launch in Serbia?
Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Serbia Patent 53,569
Patent Title: NOVA JEDINJENJA I KOMPOZICIJE, TE POSTUPCI ZA UPOTREBU (NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE)
ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC
See drug price trends for ZURAMPIC.
The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.
When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in Serbia?
Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2027
Generic Entry Controlled by: Serbia Patent 56,045
Patent Title: DERIVATI SUPSTITUISANOG 2,3-DIHIDROIMIDAZO[1,2-C]HINAZOLINA KOJI SU KORISNI ZA TRETMAN HIPER-PROLIFERATIVNIH POREMEĆAJA I BOLESTI POVEZANIH SA ANGIOGENEZOM (SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS)
ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.
See drug price trends for ALIQOPA.
The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.
When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in Serbia?
Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: Serbia Patent 61,765
Patent Title: REŽIM DOZIRANJA POVEZAN SA DUGODELUJUĆIM INJEKTABILNIM ESTRIMA PALIPERIDONA (DOSING REGIMEN ASSOCIATED WITH LONG ACTING INJECTABLE PALIPERIDONE ESTERS)

See drug price trends for INVEGA SUSTENNA.
The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.
Serbia Branded and Generic Drug Market: Regulatory Opportunities, Patent Risk, and Commercial Outlook
More… ↓
DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
